24 July 2019
If Boris Johnson is named the new UK Prime Minister, many will regard the chance of a no-deal Brexit as an uncomfortably real possibility.
Drugmakers need to prepare accordingly, and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued new guidance for active substance manufacturers in the UK.
The agency has stressed that, in the event of a no-deal, the UK will be recognized as a third country for the export of active substances for human use to the European Union (EU) and wider European Economic Area (EEA).
Written confirmation will be required for each shipment of active substances manufactured in the UK that is exported to the EEA, the guidance states.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024